Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.  Benefits of attending include: Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitorsReview clinical results from the DEMAND studyUtilise biomarkers and imaging for the development of novel cardiovascular and renal therapiesEvaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammationEnsure compliance with new FDA and EU guidelines when conducting risk-benefit assessments